Israeli generic drug maker Teva will soon complete construction of a new production hall at its plant in Gödöllő, just outside Budapest, as part of an almost HUF 30bn investment, daily Világgazdaság said on Monday, quoting communications chief Peter Paplanos.
The plant will start producing the active ingredient for the cancer drug 5-fluorouracil next year, the paper said.
Then paper notes that several hospitals in Hungary have run out of 5-fluorouracil recently. Antal Feller, CEO of pharmaceutical wholesaler Hungaropharma, said there is a shortage of the product across Europe as the plant making the drug in the Netherlands has been temporarily shut down due to a technological problem.
TEVA announced a €65m expansion at the Gödöllő plant in January 2010. The drug maker said the project, to be completed by the end of 2014, will mainly affect the production of cancer drugs, eye drops and injections. The first phase of the project was to be completed by 2011.